Clinaptis Research

Clinaptis Research

Home
Archive
About

June 2026

uniQure’s AMT-130: The FDA Changed Its Mind. The Data Didn’t.
Projecting Four-Year cUHDRS and TFC Outcomes Ahead of AMT-130’s Q3 2026 BLA, Confirmatory Trial, and Commercial Launch in Huntington's Disease (HD)
 • BK Kaler
When 45% Isn't Enough: Rethinking Disease Modification in IgAN
Reviewing Vera's Atacicept & Why the Next IgAN Winners Will Be Decided by Residual Disease Burden.
 • BK Kaler
IONS Drew First Blood. SHASTA-3/4 Is Arrowhead’s Turn
Tryngolza’s approval changes the question ahead of SHASTA-3/4. The Street will focus on headline TG reduction; we think the real readout is threshold…
 • BK Kaler
The Rise of Mini-Pharma: Why Commercial Concentration Is Replacing Platform Breadth
Concentration, commercial proof, and the rise of biotech’s new operating model.
 • BK Kaler
Axsome (AXSM): $250 Is the Problem
Auvelity is a real franchise. The ADA launch is real optionality. Neither justifies $250.
 • BK Kaler
Orexin and Narcolepsy
What the first orexin agonist approval in Narcolepsy Type I (NTI) actually validates.
 • BK Kaler
GLP-1s Solved Efficacy. They Haven't Solved Obesity
The two-leak problem in the obesity treatment funnel — and what oral drugs can and cannot fix.
 • BK Kaler
The MASH Bridge Trap
Why Rezdiffra's Market Is Smaller Than the Model
 • BK Kaler
Pancreatic Cancer Had No Druggable Target. Now It Does
Daraxonrasib in 2L PDAC: When the Data Actually Deliver
 • BK Kaler

May 2026

© 2026 Bikram Singh · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture